Recent Updates
Recently added Catalysts
PTN Positive Sentiment

Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

Key Takeaway: Palatin Technologies reported its fiscal first quarter 2027 results, highlighting advancements in its MC4R-selective obesity programs. The company is targeting Phase 1 clinical trials for its lead peptide and oral small-molecule candidates in 2027. R&D investment has significantly increased, supporting ongoing development efforts despite a reported net loss.

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancing differentiated MC4R agonists toward clinical studies.
  • Significant efficacy demonstrated in preclinical models.
  • R&D investment in obesity programs doubled year over year.
  • Potential for improved tolerability and convenience in treatments.

CONCERNS & RISKS

  • Net loss of approximately $5.1 million reported.
  • Substantial doubt regarding ability to continue as a going concern.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+277%
120-day peak, hindsight
Typical move
12.8%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
bremelanotide
Phase 2 · Obesity

Full Press Release Details

Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027
• Lead lipidated, long-acting MC4R-selective peptide advancing through IND-enabling and manufacturing activities, with Phase 1 initiation targeted for the first half of calendar 2027
• Preclinical findings demonstrate selective and potent MC4R agonism with minimal to no MC1R activity in tested peptide compounds, supporting the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation
• Expanding oral MC4R opportunities through next-generation small-molecule development and an oral peptide agonist approach
• Oral small-molecule MC4R-selective agonist Phase 1 study targeted for the second half of calendar 2027
• First-quarter R&D investment in MC4R obesity programs more than doubled year over year, reflecting advancement of key preclinical development activities
• Conference call and webcast scheduled for November 17, 2026 at 11:00 a.m. ET
PRINCETON, N.J., Nov. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines targeting the melanocortin receptor ("MCR") system, today announced financial results for its fiscal 2027 first quarter ended September 30, 2026, and provided an update on its next-generation MC4R-selective obesity development programs and strategic partnerships.
"MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "Our development strategy is specifically designed to address these challenges. We are building on more than two decades of melanocortin research and drug development experience to advance highly selective MC4R agonists with the potential to deliver robust efficacy while substantially reducing, and potentially eliminating, MC1R-mediated hyperpigmentation."
"Our lead lipidated peptide program represents a particularly compelling opportunity," continued Dr. Spana. "We have demonstrated significant efficacy with once-weekly dosing in preclinical models, and pharmacokinetic findings support the potential for once-weekly or less frequent administration in humans. Equally important, tested compounds in our next-generation peptide series have demonstrated potent MC4R activation without meaningful MC1R activation, an important attribute for developing therapies with improved long-term tolerability. We believe this combination of selectivity, efficacy and sustained activity provides a strong foundation for developing a differentiated therapy for patients who require lifelong treatment."
"During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders."

MC4R Obesity Program Update

Palatin is advancing a portfolio of MC4R-selective agonists designed to address hypothalamic obesity ("HO"), Prader-Willi syndrome ("PWS"), Bardet-Biedl syndrome ("BBS") and other rare obesity disorders associated with dysfunction of the melanocortin pathway.
The Company's strategy focuses on developing therapies with meaningful efficacy, improved gastrointestinal tolerability, reduced or eliminated MC1R-mediated hyperpigmentation, and dosing characteristics suitable for chronic treatment.

Next-Generation Long-Acting Peptide MC4R Agonists

Palatin is advancing two complementary MC4R-selective peptide series: lipidated PL2000 and non-lipidated PL1000.
• The lead lipidated PL2000 development candidate has demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration in a diet-induced obese mouse model.
• Preclinical pharmacokinetic findings support the potential for once-weekly or less frequent dosing in humans.
• Tested compounds from both peptide series have demonstrated potent MC4R agonist activity without acting as agonists at MC1R, supporting the Company's objective of substantially reducing or potentially eliminating hyperpigmentation associated with MC1R activation.
• IND-enabling studies and chemistry, manufacturing and controls ("CMC") activities are ongoing for the lead lipidated peptide candidate.
• Palatin is targeting initiation of a Phase 1 single-ascending-dose/multiple-ascending-dose ("SAD/MAD") clinical study in the first half of calendar 2027, with initial data targeted in the second half of 2027.
• The Company continues to advance its non-lipidated PL1000 peptide series, including controlled-release formulation development, as an additional approach to long-acting MC4R therapy.

Next-Generation Oral MC4R Agonists

Palatin is pursuing oral MC4R-selective therapies through its small-molecule development program and an additional oral peptide agonist approach.
The oral small-molecule program incorporates data and learnings from earlier development candidates, including PL7737, together with advanced medicinal chemistry, computational drug design, artificial intelligence and machine learning capabilities.
• Preclinical studies have identified next-generation oral small-molecule candidates with improved potency and MC4R selectivity relative to earlier compounds, together with favorable oral bioavailability.
• The program is designed to achieve meaningful efficacy with improved tolerability and minimal or no MC1R-mediated hyperpigmentation.
• Lead candidate selection and optimization activities are ongoing, with IND-enabling development targeted for the first half of calendar 2027.
• A Phase 1 SAD/MAD study is targeted to initiate in the second half of calendar 2027, with initial clinical data targeted in the first half of 2028.
• Palatin is also exploring an oral peptide agonist approach as an additional opportunity to expand its MC4R-selective therapeutic portfolio.

Partnering and Out-Licensing Programs

Retinal Diseases – Boehringer Ingelheim

Palatin continues to collaborate with Boehringer Ingelheim on proprietary melanocortin receptor-targeted compounds for retinal diseases, including diabetic retinopathy and diabetic macular edema. Palatin provides research and development support, with approved costs reimbursed by Boehringer Ingelheim.
The agreement provides for potential future development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if commercialized.
Palatin recognized approximately $0.4 million in revenue related to the collaboration during the fiscal first quarter.

PL9643 – Dry Eye Disease

Palatin's exclusive sublicense agreement with Altanispac Labs covers PL9643 for the treatment of dry eye disease. Altanispac is responsible for future development and commercialization. Palatin remains eligible for additional payments and tiered royalties under the agreement.

Additional Development and Partnering Opportunities

Palatin continues to evaluate strategic partnering and out-licensing opportunities for its bremelanotide co-administration program in obesity, PL8177 or other novel MC1R agonist in ulcerative colitis and its melanocortin receptor agonist program for diabetic nephropathy.
These programs provide opportunities to advance additional assets through strategic collaborations while maintaining Palatin's primary development focus on next-generation MC4R therapies for rare obesity disorders.

Fiscal 2027 First Quarter Ended September 30, 2026 Financial Results Revenue

For the fiscal first quarter ended September 30, 2026, Palatin recognized approximately $0.4 million in collaboration and license revenue, compared with approximately $8.8 million for the comparable prior-year period.
Revenue for the current quarter was attributable to research and development services performed under the Boehringer Ingelheim collaboration. The prior-year period included upfront and milestone revenue associated with that agreement.

Research and Development Expenses

Research and development expenses were approximately $3.4 million, compared with approximately $2.5 million for the comparable prior-year period.
R&D spending directly related to the Company's MC4R obesity programs increased to approximately $2.1 million from approximately $1.0 million in the prior-year period. The increase was primarily attributable to IND-enabling preclinical studies and related activities for the long-acting MC4R peptide program and lead candidate optimization activities for the oral small-molecule program.

General and Administrative Expenses

General and administrative expenses were approximately $2.1 million, compared with approximately $1.7 million for the comparable prior-year period. The increase was primarily attributable to higher stock-based compensation expenses and professional fees.

Net Loss

Palatin reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share, for the fiscal first quarter ended September 30, 2026.

Cash Flows and Cash Position

Net cash used in operating activities was approximately $3.7 million for the fiscal first quarter ended September 30, 2026, compared with approximately $1.6 million for the comparable prior-year period.
As of September 30, 2026, Palatin had cash and cash equivalents of approximately $3.7 million, compared with approximately $7.5 million as of June 30, 2026.
The Company intends to pursue additional financing and strategic opportunities to support continued advancement of its development programs. Additional funding will be required to execute its planned development activities and fund operations. Accordingly, substantial doubt exists regarding the Company's ability to continue as a going concern for one year following issuance of its financial statements.

Conference Call and Webcast

Palatin will host a conference call and audio webcast on November 17, 2026, at 11:00 a.m. Eastern Time, to discuss its fiscal first-quarter financial results and provide an update on corporate and development activities.
To listen to the live conference call, dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 336522. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), Replay Passcode 54837. The webcast and telephone replay will be available through December 1, 2026.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.

Forward-Looking Statements

Statements in this press release that are not historical facts, including statements regarding Palatin's product candidates, potential clinical benefits, efficacy, tolerability, receptor selectivity, dosing frequency, development programs, regulatory submissions, clinical trial initiation and results, collaborations, financing plans and future operations, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the results of preclinical and clinical studies, regulatory decisions, manufacturing and development timelines, Palatin's ability to obtain sufficient financing, the performance of collaborators and licensees, competing therapies, market conditions and other risks described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.
PALATIN TECHNOLOGIES, INC
and Subsidiary
Consolidated Statements of Operations
(unaudited)
Three Months Ended September 30,
2026 2025
REVENUES
Collaboration and license $ 361,802 $ 8,847,550
OPERATING EXPENSES
Research and development 3,383,743 2,525,766
General and administrative 2,080,414 1,660,731
Total operating expenses 5,464,157 4,186,497
(Loss) Income from operations (5,102,355) 4,661,053
OTHER INCOME (EXPENSE)
Investment income 46,534 18,483
Interest expense (1,690) (2,002)
Total other (expense) income, net 44,844 16,481
NET (LOSS) INCOME $ (5,057,511) $ 4,677,534
Basic net (loss) income per common share $ (1.29) $ 4.81
Diluted net (loss) income per common share $ (1.29) $ 4.26
Weighted average number of common shares outstanding used in computing basic net (loss) income per common share 3,922,464 971,650
Weighted average number of common shares outstanding used in computing diluted net (loss) income per common share 3,922,464 1,098,490
PALATIN TECHNOLOGIES, INC
and Subsidiary
Consolidated Balance Sheets
(unaudited)
September 30, 2026 June 30, 2026
ASSETS
Current assets:
Cash and cash equivalents $ 3,740,424 $ 7,492,014
Accounts receivable 361,802 300,770
Prepaid expenses and other current assets 337,765 371,703
Total current assets 4,439,991 8,164,487
Property and equipment, net 101,112 118,064
Right-of-use assets - operating leases 155,448 219,677
Other assets 21,626 21,626
Total assets $ 4,718,177 $ 8,523,854
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,360,530 $ 1,109,552
Accrued expenses 1,171,975 504,158
Short-term operating lease liabilities 126,661 158,263
Total current liabilities 2,659,166 1,771,973
Long-term operating lease liabilities 32,932 65,416
Total liabilities 2,692,098 1,837,389
Stockholders' equity:
Preferred stock of $0.01 par value – authorized 10,000,000 shares: shares
issued and outstanding designated as follows:
Series A Convertible: authorized 4,030 shares as of September 30, 2026: issued
and outstanding 4,030 shares as of September 30, 2026 and June 30, 2026 40 40
Series D Convertible: authorized 3,400 shares as of September 30, 2026: issued
and outstanding 3,400 shares as of September 30, 2026 and June 30, 2026 34 34
Common stock of $0.01 par value – authorized 300,000,000 shares:
issued and outstanding 1,780,939 shares as of September 30, 2026 and 1,779,275 shares as of June 30, 2026 17,809 17,793
Additional paid-in capital 474,517,501 474,120,392
Accumulated deficit (472,509,305) (467,451,794)
Total stockholders' equity 2,026,079 6,686,465
Total liabilities and stockholders' equity $ 4,718,177 $ 8,523,854
BS Check $ - $ -
Working Capital 1,780,825 6,392,514

Frequently Asked Questions

What are the key developments reported by Palatin?

Palatin is advancing MC4R-selective obesity programs and targeting Phase 1 trials in 2027.

What was Palatin's net loss for Q1 2027?

Palatin reported a net loss of approximately $5.1 million for the quarter.

When is the conference call scheduled?

The conference call is scheduled for November 17, 2026, at 11:00 a.m. ET.

How much did R&D investment increase?

R&D investment in MC4R obesity programs more than doubled year over year.

Last updated: Nov 17, 2026